Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management
Tóm tắt
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant tumour syndrome caused by germline-activating mutations of the RET proto-oncogene. It has a strong penetrance of medullary thyroid carcinoma (MTC) and can be associated with bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient or family. Based on the phenotype three distinct clinical forms have been described: (1) classical MEN2A, (2) MEN2B, an association of MTC, pheochromocytoma and mucosal neuroma and (3) familial MTC (FMTC), which is associated with a very low incidence of other endocrinopathies. Each variant of MEN2 results from a different RET gene mutation, with a good genotype-phenotype correlation with regard to aggressiveness of MTC, time of onset of MTC and the presence or absence of other endocrine tumours. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification of RET mutations into three risk levels using the genotype-phenotype correlations. MEN2 provides a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.
Tài liệu tham khảo
Raue F, Frank-Raue K, 2007 Multiple Endocrine Neoplasia Type 2: 2007 Update. Horm Res 68: 101–104.
Kouvaraki MA, Shapiro SE, Perrier ND, et al, 2005 RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15: 531–544.
Berndt I, Reuter M, Saller B, et al, 1998 A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83: 770–774.
Elisei R, Romei C, Cosci B, et al, 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92: 4725–4729.
Frank-Raue K, Rondot S, Schulze E, Raue F, 2007 Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53: 273–282.
Hubner RA, Houlston RS, 2006 Molecular advances in medullary thyroid cancer diagnosis. Clin Chim Acta 370: 2–8.
Mulligan LM, Kwok JBJ, Healey CS, et al, 1993 Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363: 458–469.
Donis-Keller H, Dou S, Chi D, et al, 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851–856.
Machens A, Niccoli-Sire P, Hoegel J, et al, 2003 for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349: 1517–1525.
Eng C, Clayton D, Schuffenecker I, et al, 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276: 1575–1579.
Yip L, Cote GL, Shapiro SE, et al, 2003 Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138: 409–416.
Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H, 2005 Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90: 3999–4003.
Quayle FJ, Fialkowski EA, Benveniste R, Moley JF, 2007 Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142: 800–805.
Schuffenecker I, Virally-Monod M, Brohet R, et al, and le Groupe d’Etude des Tumeurs a Calcitonine 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83: 487–491.
Frank-Raue K, Machens A, Scheuba, C, Niederle B, Dralle H, Raue F, and the German MEN 2 Study Group 2008 Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69: 259–263.
Brandi ML, Gagel RF, Angeli A, et al, 2001 Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 86: 5658–5671.
Frank-Raue K, Buhr H, Dralle H, et al, 2006 Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155: 229–236.
Colombo-Benkmann M, Li Z, Riemann B, et al, 2008 Characterization of the RET protooncogene transmem-brane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 158: 811–816.
Robledo M, Gil L, Pollan M, et al, 2003 Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Research 63: 1814–1817.
Cebrian A, Lesueur F, Martin S, et al, 2005 Polymorphisms in the initiators of RET (rearranged during transfection. signalling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6268–6274.
Cardot-Bauters C, Leteurtre E, Leclerc L, et al, 2008 Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol 69: 506–510.